KEY MESSAGES

• It is important to prevent, recognize and treat hypoglycemic episodes secondary to the use of insulin or insulin secretagogues.
• It is safer and more effective to prevent hypoglycemia than to treat it after it occurs, so people with diabetes who are at high risk for hypoglycemia should be identified and counselled about ways to prevent low blood glucose.
• It is important to counsel individuals who are at risk of hypoglycemia and their support persons about the recognition and treatment of hypoglycemia.
• The goals of treatment for hypoglycemia are to detect and treat a low blood glucose level promptly by using an intervention that provides the fastest rise in blood glucose to a safe level, to eliminate the risk of injury and to relieve symptoms quickly. Once the hypoglycemia has been reversed, the person should have the usual meal or snack that is due at that time of the day to prevent repeated hypoglycemia. If a meal is >1 hour away, a snack (including 15 g carbohydrate and a protein source) should be consumed.
• It is important to avoid overtreatment of hypoglycemia, since this can result in rebound hyperglycemia and weight gain.

KEY MESSAGES FOR PEOPLE WITH DIABETES

• Know the signs and symptoms of a low blood glucose level. Some of the more common symptoms of low blood glucose are trembling, sweating, anxiety, confusion, difficulty concentrating or nausea. Not all symptoms will be present and some individuals may have other or no symptoms.
• Carry a source of fast-acting carbohydrate with you at all times, such as glucose tablets, Life Savers™ and/or a juice box (see Table 4).
• Wear diabetes identification (e.g. a MedicAlert® bracelet)
• Talk with your diabetes health-care team about prevention and emergency treatment of a severe low blood glucose associated with confusion, loss of consciousness or seizure.

Introduction

Drug-induced hypoglycemia is a major obstacle for individuals trying to achieve glycemic targets. Hypoglycemia can be severe and result in confusion, coma or seizure, requiring the assistance of other individuals. Significant risk of hypoglycemia often necessitates less stringent glycemic goals. Frequency and severity of hypoglycemia negatively impact on quality of life (1) and promote fear of future hypoglycemia (2,3). This fear is associated with reduced self-care and poor glucose control (4–6). The negative social and emotional impact of hypoglycemia may make individuals reluctant to intensify therapy. As such, it is important to prevent, recognize and treat hypoglycemic episodes secondary to the use of insulin or insulin secretagogues (see Glycemic Management in Adults with Type 1 Diabetes, p. S80; Pharmacologic Glycemic Management of Type 2 Diabetes in Adults, p. S88 for further discussion of drug-induced hypoglycemia).

Definition and Frequency of Hypoglycemia

Hypoglycemia is defined by: 1) the development of autonomic or neuroglycopenic symptoms (Table 1); 2) a low plasma glucose (PG) level (<4.0 mmol/L for people with diabetes treated with insulin or an insulin secretagogue); and 3) symptoms responding to the administration of carbohydrate (7). The severity of hypoglycemia is defined by clinical manifestations (Table 2). Hypoglycemia is most frequent in people with type 1 diabetes, followed by people with type 2 diabetes managed by insulin, and people with type 2 diabetes managed by sulfonylureas.

Severe Hypoglycemia and Hypoglycemia Unawareness

The major risk factors for severe hypoglycemia in people with type 1 diabetes include a prior episode of severe hypoglycemia
Frequent hypoglycemia can decrease normal responses to hypoglycemia (12) and lead to defective glucose counter-regulation and hypoglycemia unawareness. Hypoglycemia unawareness occurs when the threshold for the development of autonomic warning symptoms is close to, or lower than, the threshold for the neuroglycopenic symptoms, such that the first sign of hypoglycemia is confusion or loss of consciousness. Severe hypoglycemia is often the primary barrier to achieving glycemic targets in people with type 1 diabetes (24) and occurs frequently during sleep or in the presence of hypoglycemia unawareness (11,25). The sympathoadrenal response to hypoglycemia is reduced during sleep, and following exercise or alcohol consumption (26,27). Asymptomatic nocturnal hypoglycemia is common and often lasts greater than 4 hours (11,28–31). Severe hypoglycemia, resulting in seizures, is more likely to occur at night than during the day (12).

Both hypoglycemia unawareness and defective glucose counter-regulation are potentially reversible. Strict avoidance of hypoglycemia and reduce the frequency of severe hypoglycemia (43,51–53). Continuous subcutaneous insulin infusion (CSII) therapy or continuous glucose monitoring (CGM) or both (i.e. a sensor augmented pump), to reduce the risk of severe hypoglycemia (44–47). Islet cell transplantation, which has been shown to reduce hypoglycemia (48) and restore glucose counter-regulation (49), should be considered for people with type 1 diabetes who experience recurrent severe hypoglycemia (50) (see Diabetes and Transplantation chapter, p. S145). Similarly, pancreas transplantation has been shown to reduce hypoglycemia and restore glucose counter-regulation (43,51–53).

Complications of Severe Hypoglycemia

Short-term risks of hypoglycemia include the dangerous situations that can arise while an individual is hypoglycemic, whether at home or at work (e.g. driving, operating machinery).

In addition, prolonged coma is sometimes associated with transient neurological symptoms, such as paresis, convulsions and encephalopathy. The potential long-term complications of severe hypoglycemia are mild intellectual impairment and permanent neuropsychological sequelae, such as hemiparesis and pontine dysfunction. The latter are rare and have been reported only in case studies. Recurrent hypoglycemia may impair the individual’s ability to sense subsequent hypoglycemia (54,55).

There is a clear association between severe hypoglycemia and cognitive disorders, but the nature of this relationship remains unclear. The person with cognitive disorders is at high risk of future severe hypoglycemic episodes, possibly because of medication errors (19,56,57) (see Diabetes in Older People chapter, p. S283). Prospective studies have not found an association between intensive insulin therapy and cognitive function (58–60), or between severe hypoglycemia and future cognitive function (56,57). Lowered cognitive performance appears to be more associated with the presence of microvascular complications or poor metabolic control than with the occurrence of severe hypoglycemic episodes (57,61).

In people with type 2 diabetes and established, or very high risk for, cardiovascular disease (CVD), there is a clear association between an increased mortality and severe hypoglycemia (62,63) and symptomatic hypoglycemia (64). The mechanism for this increase is not certain. Acute hypoglycemia is proinflammatory, increases platelet activation and decreases fibrinolysis, leading to a prothrombotic state (65,66). Hypoglycemia is associated with increased heart rate, systolic blood pressure (BP), myocardial contractility, stroke volume and cardiac output, and can induce ST- and T-wave changes with a lengthening of the QT interval (slower repolarization), which may increase the risk of arrhythmias (67–71). However, severe hypoglycemia may also be a marker of vulnerability, without any direct causal contribution to the increased mortality (72).

Treatment of Hypoglycemia

The goals of treatment for hypoglycemia are to detect and treat a low BG level promptly by using an intervention that provides the fastest rise in BG to a safe level, to eliminate the risk of injury and to relieve symptoms quickly. It is also important to avoid overtreatment since this can result in rebound hyperglycemia and weight gain. Evidence suggests that 15 g glucose (monosaccharide) is required to produce an increase in BG of approximately 2 mmol/L within 20 minutes, with adequate symptom relief for most people (Table 4) (73–77). This has not been well studied in individuals with gastroparesis. A 20 g oral glucose dose will produce a BG increment of approximately 3.6 mmol/L at 45 minutes (74,75). Other choices, such as milk and orange juice, are slower to increase BG levels and provide symptom relief (74,75). Glucose gel is quite slow (<1.0 mmol/L increase at 20 minutes) and must be swallowed to have a significant effect (73–78). People taking an alpha glucosidase

Table 3

<table>
<thead>
<tr>
<th>Risk factors for severe hypoglycemia in people treated with sulfonylureas or insulin</th>
</tr>
</thead>
<tbody>
<tr>
<td>• Prior episode of severe hypoglycemia</td>
</tr>
<tr>
<td>• Current low A1C (&lt;6.0%)</td>
</tr>
<tr>
<td>• Hypoglycemia unawareness</td>
</tr>
<tr>
<td>• Long duration of insulin therapy</td>
</tr>
<tr>
<td>• Autonomic neuropathy</td>
</tr>
<tr>
<td>• Chronic kidney disease</td>
</tr>
<tr>
<td>• Low economic status, food insecurity</td>
</tr>
<tr>
<td>• Low health literacy</td>
</tr>
<tr>
<td>• Preschool-aged children unable to detect and/or treat mild hypoglycemia on their own</td>
</tr>
<tr>
<td>• Adolescence</td>
</tr>
<tr>
<td>• Pregnancy</td>
</tr>
<tr>
<td>• Elderly</td>
</tr>
<tr>
<td>• Cognitive impairment</td>
</tr>
</tbody>
</table>

A1C, glycated hemoglobin.
Table 4

Examples of 15 g of carbohydrate for the treatment of mild-to-moderate hypoglycemia

- 15 g of glucose in the form of glucose tablets
- 15 mL (3 teaspoons) or 3 packets of table sugar dissolved in water
- 5 cubes of sugar
- 150 mL of juice or regular soft drink
- 6 Life Savers™ (1 = 2.5 g of carbohydrate)
- 15 mL (1 tablespoon) of honey

RECOMMENDATIONS

1. All people with diabetes currently using or starting therapy with insulin or insulin secretagogues and their support persons should be counselled about the risk, prevention, recognition and treatment of hypoglycemia. Risk factors for severe hypoglycemia should be identified and addressed [Grade D, Consensus].

2. The DHC team should review the person with diabetes’ experience with hypoglycemia at each visit, including an estimate of cause, frequency, symptoms, recognition, severity and treatment, as well as the risk of driving with hypoglycemia [Grade D, Consensus].

3. In people with diabetes at increased risk of hypoglycemia, the following strategies may be used to reduce the risk of hypoglycemia:
   a. Avoidance of pharmacotherapies associated with increased risk of recurrent or severe hypoglycemia (see Glycemic Management in Adults with Type 1 Diabetes, p. S80; Pharmacologic Glycemic Management of Type 2 Diabetes in Adults, p. S88, for further discussion of drug-induced hypoglycemia) [Grade D, Consensus]
   b. A standardized education program targeting rigorous avoidance of hypoglycemia while maintaining overall glycemic control [Grade B, Level 2 (83)]
   c. Increased frequency of SMBG, including periodic assessment during sleeping hours [Grade D, Consensus]
   d. Less stringent glycemic targets with avoidance of hypoglycemia for up to 3 months [Grade D, Level 4 (37,38)]
   e. A psycho-behavioural intervention program [blood glucose awareness training] [Grade C, Level 3 (40)]
   f. Structured diabetes education and frequent follow up [Grade C, Level 3 (42) for type 1 diabetes; Grade D, Consensus for type 2].

4. In people with diabetes with recurrent or severe hypoglycemia, or impaired awareness of hypoglycemia, the following strategies may be considered to reduce or eliminate the risk of severe hypoglycemia and to attempt to regain hypoglycemia awareness:
   a. Less stringent glycemic targets with avoidance of hypoglycemia for up to 3 months [Grade D, Level 4 (37,38)]
   b. CGM or sensor augmented pump with education and follow up for type 1 diabetes [Grade B, Level 2 (42,44,46,47)]
   c. Islet transplantation for type 1 diabetes [Grade C, Level 3 (48)]
   d. Pancreas transplantation for type 1 diabetes [Grade D, Level 4 (50–53)].

5. Mild-to-moderate hypoglycemia should be treated by the oral ingestion of 15 g carbohydrate, preferably as glucose or sucrose tablets or solution. These are preferable to orange juice and glucose gels [Grade B, Level 2 (73)]. People with diabetes should retest BG in 15 minutes and re-treat with another 15 g carbohydrate if the BG level remains <4.0 mmol/L [Grade D, Consensus].

6. Severe hypoglycemia in a conscious person with diabetes should be treated by oral ingestion of 20 g carbohydrate, preferably as glucose tablets or equivalent. BG should be retested in 15 minutes and then re-treated with another 15 g glucose if the BG level remains <4.0 mmol/L [Grade D, Consensus].

7. Severe hypoglycemia in an unconscious person with diabetes:
   a. With no intravenous access: 1 mg glucagon should be given subcutaneously or intramuscularly. Caregivers or support persons should call for emergency services and the episode should be discussed with the DHC team as soon as possible [Grade D, Consensus]
   b. With intravenous access: 10–25 g (20–50 mL of D50W) of glucose should be given intravenously over 1–3 minutes [Grade D, Consensus].

8. Once the hypoglycemia has been reversed, the person should have the usual meal or snack that is due at that time of the day to prevent repeated hypoglycemia. If a meal is >1 hour away, a snack (including 15 g carbohydrate and a protein source) should be consumed [Grade D, Consensus].

9. For people with diabetes at risk of severe hypoglycemia, support persons should be taught how to administer glucagon [Grade D, Consensus].

Abbreviations:
- A1C, glycated hemoglobin; BG, blood glucose; CVD, cardiovascular disease; CGM, continuous glucose monitoring; CSII, continuous subcutaneous insulin infusion; DHC, diabetes health-care team; SMBG, self-monitoring of blood glucose.

Other Relevant Guidelines

Targets for Glycemic Control, p. S42
Monitoring Glycemic Control, p. S47
Glycemic Management in Adults With Type 1 Diabetes, p. S80
Pharmacologic Glycemic Management of Type 2 Diabetes in Adults, p. S88
Diabetes and Driving, p. S150
Type 1 Diabetes in Children and Adolescents, p. S234
Type 2 Diabetes in Children and Adolescents, p. S247
Diabetes and Pregnancy, p. S255
Diabetes in Older People, p. S283

Author Disclosures

Dr. Yale reports grants and personal fees from Eli Lilly Canada, Sanofi, Merck, AstraZeneca, Boehringer Ingelheim, Janssen, and Medtronic; personal fees from Novo Nordisk, Takeda, Abbott, and Bayer; and grants from Mylan. Dr. Paty reports personal fees from Novo Nordisk, Merck, Boehringer Ingelheim, AstraZeneca, Janssen, Abbott, and Sanofi. Dr. Senior reports personal fees from Abbott, Boehringer Ingelheim, Eli Lilly, Janssen, Merck, mbriCase, and Master Clinician Alliance; grants and personal fees from Novo Nordisk, Sanofi, and AstraZeneca; grants from Prometic and ViaCyte, outside the submitted work; and Medical Director of the Clinical Islet Transplant Program at the University of Alberta Hospital, Edmonton, AB.

References


